Two drugs to raise platelets before surgery in liver disease
Part of Blood & lymphatic clinical trials.
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic liver disease and a low platelet count (35,000 or fewer).
- You are scheduled for an elective, non-emergency invasive procedure (like a biopsy or endoscopy) that is planned 9–15 days after starting the study drugs.
- You have not had a blood clot, do not have a condition that raises clot risk, and have not had a liver transplant.
- You do not have active cancer that requires chemotherapy, radiation, or other cancer treatments during the study.
- You are not on certain medications (like blood thinners or other experimental drugs) in the 90 days before the study begins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This study tests a new medicine called PN20 to safely raise platelet counts in people with chronic liver disease who need a minor procedure (like a biopsy). It's for patients whose platelet count is below 50 and whose liver disease is not too severe.
This trial tests a new combination of two medicines (hetrombopag and rhTPO) that help raise platelet counts, which often drop during cancer treatment. The goal is to see if this approach works well and is safe for people with low platelets caused by cancer therapy.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests a medicine called lusutrombopag to help raise low platelet counts after a stem cell transplant from a half-matched family donor. It may be a good option for people who are recovering from transplant and need help with their blood counts.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.